According to the most recent report, McClarren Financial Advisors Inc. filed with the Securities and Exchange Commission (SEC), the company acquired a new stake in Pfizer Inc. (NYSE: PFE) during the third quarter of the current fiscal year. The institutional investor spent nearly 204,000 dollars to purchase 4,682 shares of stock in the biopharmaceutical company. These shares were purchased in total.
Other significant investors in the company have recently made changes to the proportion of ownership that they hold in the company. The percentage of Pfizer stock that Steward Financial Group LLC owns went up by 315.3 percent during the second quarter as a result of the company’s purchases. Steward Financial Group LLC now has 544 shares of the biopharmaceutical business, with a market cap of $28,000. This is because, during this period, the company made an additional purchase of 413 shares, bringing the total number of shares owned by the company to 544. During the first three months of 2018, Worth Asset Management LLC spent close to 30,000 dollars to acquire a new position at Pfizer. During the second quarter, Goodman Advisory Group LLC acquired a new investment in Pfizer stock that came to approximately 32 thousand dollars in total value. Karp Capital Management Corporation made a Pfizer investment of $27,000 during the third quarter of the fiscal year. During the second quarter, Johnson Midwest Financial LLC increased the total value of its holdings in Pfizer by 246.1%. Johnson Midwest Financial LLC now holds 886 shares of the biopharmaceutical company’s stock, following the acquisition of an additional 630 shares during the most recent quarter. The value of Johnson Midwest Financial LLC’s stock holdings in the biopharmaceutical company is approximately $46,000. Institutional investors own the common shares of the company to the extent of 67.62%.
PDF began trading at $47.71 on Friday. A debt-to-equity ratio comes in at 0.35; a quick ratio comes in at 1.37; a current ratio comes in at 1.58; and a quick ratio comes in at 1.37. The stock has a price-to-earnings ratio of 9.18, a price-to-earnings-to-growth ratio of 1.15, and a beta value of 0.67. Its current market value is 267.81 billion dollars. The company has a simple moving average of $48.47, both for the last 50 days and the last 200 days. The company is currently priced at $49.97.Pfizer Inc. has seen a low point over the past 52 weeks of $41.44, while the company has seen a high point over the past 52 weeks of $56.75.
On November 1st, Pfizer (NYSE: PFE) disseminated the quarterly results report that it had prepared to the general public. The biopharmaceutical company’s earnings per share for the quarter came in at $1.78, which was $0.31 higher than the consensus prediction of $1.47. The sales figures for the company for the quarter came in significantly higher than the predictions made by the analysts, which were $21.04 billion, coming in at $22.64 billion instead. According to their financial reports, Pfizer had a net margin of 29.81% and a return on equity of 43.95%, respectively. Pfizer Inc. is expected to achieve earnings of $6.46 per share in 2018, according to the projections of market analysts.
In addition, the business just announced a quarterly dividend, which will be distributed on March 3, according to the plan. On the 27th of January, registered shareholders will be eligible to receive a $0.41 dividend payment per share. The date that shareholders will no longer receive dividends is Thursday, the 26th of January. This results in a yield of 3.44 percent and an annual dividend payment of 1.64 dollars. Pfizer has increased the previous $0.40 that it distributed to shareholders every quarter in the form of a dividend. At the moment, Pfizer is paying out dividends to its shareholders, amounting to 30.77 percent of the company’s earnings.
PFE has been the subject of several studies carried out and published not too long ago. Bank of America lowered its rating on shares of Pfizer from “buy” to “neutral” and set a price objective of $60.00 for the stock in a research note dated Wednesday, January 4th. The note also stated that the firm has a price objective of $60.00 for the stock. In a research note published on November 2, Barclays increased their price objective on Pfizer shares from $44.00 to $49.00 and classified the stock as “equal weight.” The price target that SVB Leerink has set for Pfizer shares has increased from $48.00 to $49.00, as stated in a research note published on Thursday, November 3rd. In addition, they rated the stock as “market perform,” which means it should perform similarly to the market. On October 12th, StockNews.com was the first website to publish an in-depth research analysis regarding Pfizer shares. The article was published on the website. They encouraged potential buyers to “strongly purchase” the stock. According to a research note released Tuesday by JPMorgan Chase & Co., the firm has determined that the appropriate price target for Pfizer shares is $50.00. This stock has been recommended to be held by six different analysts, while it has been given a buy rating by three analysts and a strong buy rating by one. Bloomberg has assigned Pfizer a “Moderate Buy” rating, and the average price target for the company’s shares is $55.15, as reported by that source.
Pfizer Inc. is an international pharmaceutical company that conducts research and development, production, marketing, distribution, and sales of biopharmaceutical products. It provides drugs and vaccines for a wide variety of medical conditions, including cardiovascular disease, metabolic disease, and women’s health under the Premarin family and Eliquis brand names; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit,